A recent study reveals that individuals who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional diet and exercise programs.
Published data in a major medical journal points out that while obese people can lose about a fifth of their total mass while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Users using these medications need to be aware of the potential of rapid rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment weight in about 18 months.
Analyzing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
The team emphasize that people who shed pounds through diet and exercise usually see a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Experts propose the way of the injections explains the accelerated rebound.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals argue that, given the likelihood of weight regain, the treatment should be considered long-term.
This perspective is supported by pharmaceutical companies, who state that the results "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
Patient Testimonies
Individuals who have come off the medication report a intense return of hunger.
"I experienced a trigger flipping and you're instantly extremely hungry," said one woman.
This challenge is exacerbated if users have not adopted lasting lifestyle or habit changes during therapy.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and maintained weight loss likely depends on integrated lifestyle management.
